RemeGen Closes Over USD $100M Funding Round
Summary
Loyal Valley Capital and China Reform Conson Soochow Overseas Fund also invested through the purchase from existing shareholders. Founded in 2008 led by Jianmin Fang, Ph.D., CEO, RemeGen is a biopharmaceutical company with fully integrated capabilities in research and discovery, clinical development, manufacturing and commercialization of biologic drugs. The company is focused on the research and development of innovative biologics in the therapeutic areas of autoimmune, cancer and ophthalmology diseases. Telitacicept is a fusion protein with a new drug application filed in China for systemic lupus erythematosus (SLE). RC48, a HER2 ADC for the treatment of various solid tumors, is currently in pivotal clinical trials for gastric and urothelial cancers.